Clinical Trials Logo

Angina Pectoris, Variant clinical trials

View clinical trials related to Angina Pectoris, Variant.

Filter by:

NCT ID: NCT02094469 Completed - Vasospastic Angina Clinical Trials

Safety and Efficacy Study of Cilostazol to Treat Vasospastic Angina

STELLA_Ext
Start date: December 2013
Phase: Phase 3
Study type: Interventional

This study will be conducted in accordance with the local regulation of New Drug Application. Overall duration of this trial will be 3 years after approval of MFDS. Each subject will participate around 26 weeks, which include the 24 weeks treatment period and 2 weeks safety follow up period. Withdrawn subjects due to efficacy after 4 weeks treatment will participate in 6 weeks in total including 2 weeks safety follow up. Withdrawn subjects with other reason also have 2 weeks follow up period.

NCT ID: NCT02087007 Completed - Vasospastic Angina Clinical Trials

A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina

STELLA
Start date: November 2013
Phase: Phase 3
Study type: Interventional

This study will be conducted in accordance with the local regulation of New Drug Application. Overall duration of this trial will be 3 years after approval of KFDA. Each subject will participate around 7 weeks, which include the 2 weeks Amlodipine run-in period, 4 weeks double blind period and 1 week safety follow up period

NCT ID: NCT01674686 Recruiting - Variant Angina Clinical Trials

The Effect of Sarpogrelate and High Dose Statin on the Reduction of Coronary Spasm

Start date: August 1, 2012
Phase: Phase 4
Study type: Interventional

The aim of the study was to to evaluate the effect of sarpogrelate, a selective serotonin receptor antagonist, and high dose statin on the reduction of coronary spasm in the patients with variant angina.

NCT ID: NCT01444885 Completed - Variant Angina Clinical Trials

Evaluate the Efficacy and Safety of Pletaal (Cilostazol) in Subjects With Vasospastic Angina

STELLA
Start date: October 2011
Phase: Phase 2
Study type: Interventional

The objective of this study is to investigate the efficacy and safety of Pletaal (Cilostazol) in comparison with placebo for 4 weeks in vasospastic angina patients who have an insufficient response to Amlodipine (Calcium channel blocker).

NCT ID: NCT01318629 Active, not recruiting - Angina Pectoris Clinical Trials

Angina in Non Coronary Artery Disease

HeartQuest
Start date: July 1996
Phase: N/A
Study type: Observational

Many patients undergoing coronary angiography are found to have no significant coronary artery disease (CAD) despite angina equivalent symptoms and/or electrocardiographic abnormalities suggestive of myocardial ischemia. The aim of this study is to systematically assess patients with angina equivalent symptoms despite normal coronary angiograms and to evaluate their symptoms according to a defined algorithm.

NCT ID: NCT00620204 Recruiting - Clinical trials for Angina Pectoris, Variant

Efficacy Study of Atorvastatin to Treat Variant Angina

ESAVA
Start date: January 2008
Phase: Phase 4
Study type: Interventional

The objective of this study is to evaluate effect of statin treatment for vasospastic angina.

NCT ID: NCT00602017 Completed - Hypertension Clinical Trials

Bioequivalency Study of Amlodipine Tablets Under Fasting Conditions

Start date: April 2004
Phase: N/A
Study type: Interventional

The objective of this study was the bioequivalence of a Roxane Laboratories' Amlodipine Besylate tablets, 10 mg, to Norvasc® Tablets, 10 mg (Pfizer) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.

NCT ID: NCT00601302 Completed - Hypertension Clinical Trials

Bioequivalency Study of Amlodipine Tablets Under Fed Conditions

Start date: April 2004
Phase: N/A
Study type: Interventional

The objective of this study was the bioequivalence of a Roxane Laboratories' Amlodipine Besylate tablets, 10 mg, to Norvasc® Tablets, 10 mg (Pfizer) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.